Format

Send to

Choose Destination
BMC Med. 2015 Sep 14;13:219. doi: 10.1186/s12916-015-0463-8.

Blood-based gene expression profiling in castrate-resistant prostate cancer.

Author information

1
Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, 9033 Wilshire Boulevard, Suite 300, Beverly Hills, CA, 90211, USA. mitchell.gross@usc.edu.

Abstract

Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer, has recently been the focus of many successful new treatments. Contemporary trials highlight the heterogeneous prognosis of CRPC as overall survival times vary greatly across different patient sub-groups. As presented in BMC Medicine, Wang et al. identify a blood-based prognostic signature in CRPC. Their approach is notable for discovery and validation of a four-gene model based on a whole-blood expression signature sampled from three distinct clinical cohorts. Further, the marker selection process incorporates an understanding of biological pathways expressed in myeloid or lymphoid cells which may provide some insight into host-tumor interactions as reflected in the peripheral blood. While the study includes a multivariate analysis accounting for many important clinical variables, larger datasets with more complete clinical information and sufficient follow-up are needed to confirm the independent significance of the four-gene expression model in a way which may better inform the care of CRPC patients.Please see related article: http://www.biomedcentral.com/1741-7015/13/201 .

PMID:
26365516
PMCID:
PMC4568585
DOI:
10.1186/s12916-015-0463-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center